newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

Received Priority Review and Acceptance for Filing of the NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich's Ataxia Anno